Case Reports in Oncology · Published 2026-08-04 · DOI 10.1159/000552719
Morimi Fujita, Ninso Matsunaga, Hiroyuki Tsuji, Yosuke Tamura, Kenjiro Tsuruoka, Takahiko Nakamura, Soichiro Ikeda, Yasuhito Fujisaka
Introduction: Patients undergoing maintenance hemodialysis exhibit a unique immunological state characterized by chronic inflammation and T-cell dysfunction. Evidence regarding the efficacy and safety of combination chemoimmunotherapy in dialysis patients remains extremely limited. Case Report: We report a case of extensive-stage small cell lung cancer (ES-SCLC; performance status 1, cT1cN2M1c, stage IVB) in a patient undergoing maintenance hemodialysis who received four cycles of carboplatin (300 mg/m², day 1), etoposide (50 mg/m², days 1 and 3), and durvalumab (1,500 mg/body, day 1). Treatment was safely continued after adjusting the dosing schedule and dose levels in accordance with the dialysis schedule. Although new brain metastases developed during treatment and whole-brain radiotherapy was administered, computed tomography after four cycles demonstrated a partial response, and durvalumab maintenance therapy was subsequently continued. Grade 4 thrombocytopenia and grade 3 anemia and neutropenia were observed as adverse events; however, these were manageable with transfusion support and dose reduction. Disease progression was subsequently observed. Conclusion: Carboplatin, etoposide, and durvalumab can provide meaningful therapeutic benefit even in patients undergoing maintenance hemodialysis when adverse events are appropriately managed.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Fujita, M., Matsunaga, N., Tsuji, H., et al. (2026). Carboplatin, Etoposide, and Durvalumab for Extensive-Stage Small Cell Lung Cancer in a Patient Undergoing Maintenance Hemodialysis: A Case Report. Case Reports in Oncology. https://doi.org/10.1159/000552719